BRD2 and cancer: Examination of the missense mutational count for the first five amino acid residues (P1-P5) across the TCGA pan-cancer study found similar levels for each amino acid position, thus mutations of the first two amino acids that would be associated with NAT regulation are not globally enriched in cancers (Figure 2B).